Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Immunogenicity and Safety of the Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) in Healthy Infants Via a Randomized, Double-blind, Active-controlled Phase II Clinical Trial.

NCT06967272 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.

NCT NCT06967272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06967272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Immunogenicity and Safety of the Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) in Healthy Infants Via a Randomized, Double-blind, Active-controlled Phase II Clinical Trial.
Lead sponsor
Sinovac Life Sciences Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
January 20, 2025
Completion date
November 15, 2026
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rotavirus gastroenteritis